GSK2879552 / GSK  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK2879552 / GSK
NCT02034123: Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

Terminated
1
29
Europe, US
GSK2879552
GlaxoSmithKline
Carcinoma, Small Cell
04/17
04/17
NCT02177812: A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Terminated
1
41
Canada, US, RoW
GSK2879552, ATRA
GlaxoSmithKline
Leukaemia, Myelocytic, Acute
12/17
12/17

Download Options